메뉴 건너뛰기




Volumn 230, Issue 4, 2013, Pages 430-440

Dasatinib inhibits mammary tumour development in a genetically engineered mouse model

Author keywords

breast cancer; dasatinib; mouse model; Src

Indexed keywords

BETA CATENIN; CRE RECOMBINASE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UVOMORULIN;

EID: 84880110588     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4202     Document Type: Article
Times cited : (12)

References (67)
  • 1
    • 1842584776 scopus 로고    scopus 로고
    • Newest findings on the oldest oncogene; How activated src does it
    • Frame MC,. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004; 117: 989-998.
    • (2004) J Cell Sci , vol.117 , pp. 989-998
    • Frame, M.C.1
  • 2
    • 7944236785 scopus 로고    scopus 로고
    • Src family kinases, key regulators of signal transduction
    • Parsons SJ, Parsons JT,. Src family kinases, key regulators of signal transduction. Oncogene 2004; 23: 7906-7909.
    • (2004) Oncogene , vol.23 , pp. 7906-7909
    • Parsons, S.J.1    Parsons, J.T.2
  • 3
    • 0038386613 scopus 로고    scopus 로고
    • Src family kinases in tumor progression and metastasis
    • Summy JM, Gallick GE,. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-358.
    • (2003) Cancer Metastasis Rev , vol.22 , pp. 337-358
    • Summy, J.M.1    Gallick, G.E.2
  • 4
    • 51449088226 scopus 로고    scopus 로고
    • Src and focal adhesion kinase as therapeutic targets in cancer
    • Brunton VG, Frame MC,. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 2008; 8: 427-432.
    • (2008) Curr Opin Pharmacol , vol.8 , pp. 427-432
    • Brunton, V.G.1    Frame, M.C.2
  • 5
    • 77956042544 scopus 로고    scopus 로고
    • SRC: A century of science brought to the clinic
    • Aleshin A, Finn RS,. SRC: a century of science brought to the clinic. Neoplasia 2010; 12: 599-607.
    • (2010) Neoplasia , vol.12 , pp. 599-607
    • Aleshin, A.1    Finn, R.S.2
  • 6
    • 84861491693 scopus 로고    scopus 로고
    • Src kinase inhibitors: Promising cancer therapeutics?
    • Creedon H, Brunton VG,. Src kinase inhibitors: promising cancer therapeutics? Crit Rev Oncog 2012; 17: 145-159.
    • (2012) Crit Rev Oncog , vol.17 , pp. 145-159
    • Creedon, H.1    Brunton, V.G.2
  • 7
    • 77954690732 scopus 로고    scopus 로고
    • Advances in targeting SRC in the treatment of breast cancer and other solid malignancies
    • Mayer EL, Krop IE,. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16: 3526-3532.
    • (2010) Clin Cancer Res , vol.16 , pp. 3526-3532
    • Mayer, E.L.1    Krop, I.E.2
  • 8
    • 73549112454 scopus 로고    scopus 로고
    • Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?
    • Elsberger B, Tan BA, Mitchell TJ, et al,. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am J Pathol 2009; 175: 1389-1397.
    • (2009) Am J Pathol , vol.175 , pp. 1389-1397
    • Elsberger, B.1    Tan, B.A.2    Mitchell, T.J.3
  • 9
    • 79959362334 scopus 로고    scopus 로고
    • Clinicopathological significance of Y416Src and Y527Src expression in breast cancer
    • Kanomata N, Kurebayashi J, Kozuka Y, et al,. Clinicopathological significance of Y416Src and Y527Src expression in breast cancer. J Clin Pathol 2011; 64: 578-586.
    • (2011) J Clin Pathol , vol.64 , pp. 578-586
    • Kanomata, N.1    Kurebayashi, J.2    Kozuka, Y.3
  • 10
    • 8344223854 scopus 로고    scopus 로고
    • Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: Implications for cell proliferation
    • Shupnik MA,. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004; 23: 7979-7989.
    • (2004) Oncogene , vol.23 , pp. 7979-7989
    • Shupnik, M.A.1
  • 11
    • 79959249550 scopus 로고    scopus 로고
    • Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
    • Chen Y, Alvarez EA, Azzam D, et al,. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res Treat 2011; 128: 69-78.
    • (2011) Breast Cancer Res Treat , vol.128 , pp. 69-78
    • Chen, Y.1    Alvarez, E.A.2    Azzam, D.3
  • 12
    • 66149160364 scopus 로고    scopus 로고
    • Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors
    • Chen Y, Guggisberg N, Jorda M, et al,. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 2009; 15: 3396-3405.
    • (2009) Clin Cancer Res , vol.15 , pp. 3396-3405
    • Chen, Y.1    Guggisberg, N.2    Jorda, M.3
  • 13
    • 33846235881 scopus 로고    scopus 로고
    • Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells
    • Herynk MH, Beyer AR, Cui Y, et al,. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 2006; 5: 3023-3031.
    • (2006) Mol Cancer Ther , vol.5 , pp. 3023-3031
    • Herynk, M.H.1    Beyer, A.R.2    Cui, Y.3
  • 14
    • 33846870586 scopus 로고    scopus 로고
    • Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer
    • Hiscox S, Morgan L, Green T, et al,. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006; 13 (Suppl 1): S53-S59.
    • (2006) Endocr Relat Cancer , vol.13 , Issue.SUPPL. 1
    • Hiscox, S.1    Morgan, L.2    Green, T.3
  • 15
    • 82955234094 scopus 로고    scopus 로고
    • Significance of ER-Src axis in hormonal therapy resistance
    • Vallabhaneni S, Nair BC, Cortez V, et al,. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat 2011; 130: 377-385.
    • (2011) Breast Cancer Res Treat , vol.130 , pp. 377-385
    • Vallabhaneni, S.1    Nair, B.C.2    Cortez, V.3
  • 16
    • 4544235743 scopus 로고    scopus 로고
    • C-Src and cooperating partners in human cancer
    • Ishizawar R, Parsons SJ,. c-Src and cooperating partners in human cancer. Cancer Cell 2004; 6: 209-214.
    • (2004) Cancer Cell , vol.6 , pp. 209-214
    • Ishizawar, R.1    Parsons, S.J.2
  • 17
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, et al,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 18
    • 79953745096 scopus 로고    scopus 로고
    • Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
    • Zhang S, Huang WC, Li P, et al,. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Med 2011; 17: 461-469.
    • (2011) Nature Med , vol.17 , pp. 461-469
    • Zhang, S.1    Huang, W.C.2    Li, P.3
  • 19
    • 19944428353 scopus 로고    scopus 로고
    • Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
    • Lombardo LJ, Lee FY, Chen P, et al,. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661.
    • (2004) J Med Chem , vol.47 , pp. 6658-6661
    • Lombardo, L.J.1    Lee, F.Y.2    Chen, P.3
  • 20
    • 34548701082 scopus 로고    scopus 로고
    • Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/'triple-negative' breast cancer cell lines growing in vitro
    • Finn RS, Dering J, Ginther C, et al,. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/'triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-326.
    • (2007) Breast Cancer Res Treat , vol.105 , pp. 319-326
    • Finn, R.S.1    Dering, J.2    Ginther, C.3
  • 21
    • 33947225176 scopus 로고    scopus 로고
    • Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
    • Huang F, Reeves K, Han X, et al,. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007; 67: 2226-2238.
    • (2007) Cancer Res , vol.67 , pp. 2226-2238
    • Huang, F.1    Reeves, K.2    Han, X.3
  • 22
    • 33846241683 scopus 로고    scopus 로고
    • Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib
    • Serrels A, Macpherson IR, Evans TR, et al,. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006; 5: 3014-3022.
    • (2006) Mol Cancer Ther , vol.5 , pp. 3014-3022
    • Serrels, A.1    Macpherson, I.R.2    Evans, T.R.3
  • 23
    • 33745243692 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival
    • Song L, Morris M, Bagui T, et al,. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006; 66: 5542-5548.
    • (2006) Cancer Res , vol.66 , pp. 5542-5548
    • Song, L.1    Morris, M.2    Bagui, T.3
  • 24
    • 56449100212 scopus 로고    scopus 로고
    • Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells
    • Buettner R, Mesa T, Vultur A, et al,. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008; 6: 1766-1774.
    • (2008) Mol Cancer Res , vol.6 , pp. 1766-1774
    • Buettner, R.1    Mesa, T.2    Vultur, A.3
  • 25
    • 77953898050 scopus 로고    scopus 로고
    • Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma
    • Morton JP, Karim SA, Graham K, et al,. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2010; 139: 292-303.
    • (2010) Gastroenterology , vol.139 , pp. 292-303
    • Morton, J.P.1    Karim, S.A.2    Graham, K.3
  • 26
    • 27144547509 scopus 로고    scopus 로고
    • Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
    • Nam S, Kim D, Cheng JQ, et al,. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189.
    • (2005) Cancer Res , vol.65 , pp. 9185-9189
    • Nam, S.1    Kim, D.2    Cheng, J.Q.3
  • 27
    • 66149164441 scopus 로고    scopus 로고
    • SRC family kinase activity is up-regulated in hormone-refractory prostate cancer
    • Tatarov O, Mitchell TJ, Seywright M, et al,. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009; 15: 3540-3549.
    • (2009) Clin Cancer Res , vol.15 , pp. 3540-3549
    • Tatarov, O.1    Mitchell, T.J.2    Seywright, M.3
  • 28
    • 44849134528 scopus 로고    scopus 로고
    • Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model
    • Park SI, Zhang J, Phillips KA, et al,. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68: 3323-3333.
    • (2008) Cancer Res , vol.68 , pp. 3323-3333
    • Park, S.I.1    Zhang, J.2    Phillips, K.A.3
  • 29
    • 33644647192 scopus 로고    scopus 로고
    • Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
    • Trevino JG, Summy JM, Lesslie DP, et al,. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006; 168: 962-972.
    • (2006) Am J Pathol , vol.168 , pp. 962-972
    • Trevino, J.G.1    Summy, J.M.2    Lesslie, D.P.3
  • 30
    • 80455173400 scopus 로고    scopus 로고
    • Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study
    • Finn RS, Bengala C, Ibrahim N, et al,. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011; 17: 6905-6913.
    • (2011) Clin Cancer Res , vol.17 , pp. 6905-6913
    • Finn, R.S.1    Bengala, C.2    Ibrahim, N.3
  • 31
    • 80455132309 scopus 로고    scopus 로고
    • A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer
    • Mayer EL, Baurain JF, Sparano J, et al,. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011; 17: 6897-6904.
    • (2011) Clin Cancer Res , vol.17 , pp. 6897-6904
    • Mayer, E.L.1    Baurain, J.F.2    Sparano, J.3
  • 32
    • 0034724314 scopus 로고    scopus 로고
    • Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis
    • Andrechek ER, Hardy WR, Siegel PM, et al,. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci U S A 2000; 97: 3444-3449.
    • (2000) Proc Natl Acad Sci U S A , vol.97 , pp. 3444-3449
    • Andrechek, E.R.1    Hardy, W.R.2    Siegel, P.M.3
  • 33
    • 42049084166 scopus 로고    scopus 로고
    • Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis
    • Dourdin N, Schade B, Lesurf R, et al,. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 2008; 68: 2122-2131.
    • (2008) Cancer Res , vol.68 , pp. 2122-2131
    • Dourdin, N.1    Schade, B.2    Lesurf, R.3
  • 34
    • 0037136697 scopus 로고    scopus 로고
    • Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency
    • Gallagher RC, Hay T, Meniel V, et al,. Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency. Oncogene 2002; 21: 6446-6457.
    • (2002) Oncogene , vol.21 , pp. 6446-6457
    • Gallagher, R.C.1    Hay, T.2    Meniel, V.3
  • 35
    • 0032171148 scopus 로고    scopus 로고
    • Efficient BLG-Cre mediated gene deletion in the mammary gland
    • Selbert S, Bentley DJ, Melton DW, et al,. Efficient BLG-Cre mediated gene deletion in the mammary gland. Transgenic Res 1998; 7: 387-396.
    • (1998) Transgenic Res , vol.7 , pp. 387-396
    • Selbert, S.1    Bentley, D.J.2    Melton, D.W.3
  • 36
    • 0036714806 scopus 로고    scopus 로고
    • Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland
    • Li G, Robinson GW, Lesche R, et al,. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002; 129: 4159-4170.
    • (2002) Development , vol.129 , pp. 4159-4170
    • Li, G.1    Robinson, G.W.2    Lesche, R.3
  • 37
    • 65549088630 scopus 로고    scopus 로고
    • Tracing pathway activities with kinase inhibitors and reverse phase protein arrays
    • van Oostrum J, Calonder C, Rechsteiner D, et al,. Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteomics Clin Appl 2009; 3: 412-422.
    • (2009) Proteomics Clin Appl , vol.3 , pp. 412-422
    • Van Oostrum, J.1    Calonder, C.2    Rechsteiner, D.3
  • 38
    • 0037103985 scopus 로고    scopus 로고
    • Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors
    • Miyoshi K, Rosner A, Nozawa M, et al,. Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene 2002; 21: 5548-5556.
    • (2002) Oncogene , vol.21 , pp. 5548-5556
    • Miyoshi, K.1    Rosner, A.2    Nozawa, M.3
  • 39
    • 0037039355 scopus 로고    scopus 로고
    • Activation of beta-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias
    • Miyoshi K, Shillingford JM, Le Provost F, et al,. Activation of beta-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci U S A 2002; 99: 219-224.
    • (2002) Proc Natl Acad Sci U S A , vol.99 , pp. 219-224
    • Miyoshi, K.1    Shillingford, J.M.2    Le Provost, F.3
  • 40
    • 51849140016 scopus 로고    scopus 로고
    • Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor
    • Luo FR, Barrett YC, Yang Z, et al,. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008; 62: 1065-1074.
    • (2008) Cancer Chemother Pharmacol , vol.62 , pp. 1065-1074
    • Luo, F.R.1    Barrett, Y.C.2    Yang, Z.3
  • 41
    • 78549246804 scopus 로고    scopus 로고
    • Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: Effects on E-cadherin dynamics
    • Canel M, Serrels A, Miller D, et al,. Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res 2010; 70: 9413-9422.
    • (2010) Cancer Res , vol.70 , pp. 9413-9422
    • Canel, M.1    Serrels, A.2    Miller, D.3
  • 42
    • 66149100509 scopus 로고    scopus 로고
    • Real-time study of E-cadherin and membrane dynamics in living animals: Implications for disease modeling and drug development
    • Serrels A, Timpson P, Canel M, et al,. Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug development. Cancer Res 2009; 69: 2714-2719.
    • (2009) Cancer Res , vol.69 , pp. 2714-2719
    • Serrels, A.1    Timpson, P.2    Canel, M.3
  • 43
    • 0029097471 scopus 로고
    • Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene
    • Webster MA, Cardiff RD, Muller WJ,. Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene. Proc Natl Acad Sci U S A 1995; 92: 7849-7853.
    • (1995) Proc Natl Acad Sci U S A , vol.92 , pp. 7849-7853
    • Webster, M.A.1    Cardiff, R.D.2    Muller, W.J.3
  • 44
    • 84857402960 scopus 로고    scopus 로고
    • Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis
    • Marcotte R, Smith HW, Sanguin-Gendreau V, et al,. Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proc Natl Acad Sci U S A 2012; 109: 2808-2813.
    • (2012) Proc Natl Acad Sci U S A , vol.109 , pp. 2808-2813
    • Marcotte, R.1    Smith, H.W.2    Sanguin-Gendreau, V.3
  • 45
    • 78751642736 scopus 로고    scopus 로고
    • Control of mammary tumor differentiation by SKI-606 (bosutinib)
    • Hebbard L, Cecena G, Golas J, et al,. Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene 2011; 30: 301-312.
    • (2011) Oncogene , vol.30 , pp. 301-312
    • Hebbard, L.1    Cecena, G.2    Golas, J.3
  • 46
    • 60149091984 scopus 로고    scopus 로고
    • A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model
    • Serrels B, Serrels A, Mason SM, et al,. A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. Carcinogenesis 2009; 30: 249-257.
    • (2009) Carcinogenesis , vol.30 , pp. 249-257
    • Serrels, B.1    Serrels, A.2    Mason, S.M.3
  • 47
    • 33847728182 scopus 로고    scopus 로고
    • A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo
    • Jallal H, Valentino ML, Chen G, et al,. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007; 67: 1580-1588.
    • (2007) Cancer Res , vol.67 , pp. 1580-1588
    • Jallal, H.1    Valentino, M.L.2    Chen, G.3
  • 48
    • 26444468152 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells
    • Johnson FM, Saigal B, Talpaz M, et al,. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11: 6924-6932.
    • (2005) Clin Cancer Res , vol.11 , pp. 6924-6932
    • Johnson, F.M.1    Saigal, B.2    Talpaz, M.3
  • 49
    • 67649846431 scopus 로고    scopus 로고
    • Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
    • Pichot CS, Hartig SM, Xia L, et al,. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009; 101: 38-47.
    • (2009) Br J Cancer , vol.101 , pp. 38-47
    • Pichot, C.S.1    Hartig, S.M.2    Xia, L.3
  • 50
    • 34047265691 scopus 로고    scopus 로고
    • Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival
    • Shor AC, Keschman EA, Lee FY, et al,. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007; 67: 2800-2808.
    • (2007) Cancer Res , vol.67 , pp. 2800-2808
    • Shor, A.C.1    Keschman, E.A.2    Lee, F.Y.3
  • 51
    • 33644532202 scopus 로고    scopus 로고
    • SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling
    • Coluccia AM, Benati D, Dekhil H, et al,. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 2006; 66: 2279-2286.
    • (2006) Cancer Res , vol.66 , pp. 2279-2286
    • Coluccia, A.M.1    Benati, D.2    Dekhil, H.3
  • 52
    • 0028174305 scopus 로고
    • Involvement of pp60c-src with two major signaling pathways in human breast cancer
    • Luttrell DK, Lee A, Lansing TJ, et al,. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci U S A 1994; 91: 83-87.
    • (1994) Proc Natl Acad Sci U S A , vol.91 , pp. 83-87
    • Luttrell, D.K.1    Lee, A.2    Lansing, T.J.3
  • 53
    • 0029165834 scopus 로고
    • Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor
    • Muthuswamy SK, Muller WJ,. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene 1995; 11: 271-279.
    • (1995) Oncogene , vol.11 , pp. 271-279
    • Muthuswamy, S.K.1    Muller, W.J.2
  • 54
    • 0028047315 scopus 로고
    • Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity
    • Muthuswamy SK, Siegel PM, Dankort DL, et al,. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 1994; 14: 735-743.
    • (1994) Mol Cell Biol , vol.14 , pp. 735-743
    • Muthuswamy, S.K.1    Siegel, P.M.2    Dankort, D.L.3
  • 55
    • 0035932351 scopus 로고    scopus 로고
    • Src family kinases and HER2 interactions in human breast cancer cell growth and survival
    • Belsches-Jablonski AP, Biscardi JS, Peavy DR, et al,. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001; 20: 1465-1475.
    • (2001) Oncogene , vol.20 , pp. 1465-1475
    • Belsches-Jablonski, A.P.1    Biscardi, J.S.2    Peavy, D.R.3
  • 56
    • 27844600580 scopus 로고    scopus 로고
    • The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: Implications for ErbB-2 mediated signaling and transformation
    • Kim H, Chan R, Dankort DL, et al,. The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene 2005; 24: 7599-7607.
    • (2005) Oncogene , vol.24 , pp. 7599-7607
    • Kim, H.1    Chan, R.2    Dankort, D.L.3
  • 57
    • 70350539312 scopus 로고    scopus 로고
    • C-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential
    • Marcotte R, Zhou L, Kim H, et al,. c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol Cell Biol 2009; 29: 5858-5871.
    • (2009) Mol Cell Biol , vol.29 , pp. 5858-5871
    • Marcotte, R.1    Zhou, L.2    Kim, H.3
  • 58
    • 33745230142 scopus 로고    scopus 로고
    • Role of SRC kinases in Neu-induced tumorigenesis: Challenging the paradigm using Csk homologous kinase transgenic mice
    • Kaminski R, Zagozdzon R, Fu Y, et al,. Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice. Cancer Res 2006; 66: 5757-5762.
    • (2006) Cancer Res , vol.66 , pp. 5757-5762
    • Kaminski, R.1    Zagozdzon, R.2    Fu, Y.3
  • 59
    • 77952114407 scopus 로고    scopus 로고
    • Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
    • Moulder S, Yan K, Huang F, et al,. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 2010; 9: 1120-1127.
    • (2010) Mol Cancer Ther , vol.9 , pp. 1120-1127
    • Moulder, S.1    Yan, K.2    Huang, F.3
  • 60
    • 84859964339 scopus 로고    scopus 로고
    • Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects
    • Garcia-Gomez A, Ocio EM, Crusoe E, et al,. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One 2012; 7: e34914.
    • (2012) PLoS One , vol.7
    • Garcia-Gomez, A.1    Ocio, E.M.2    Crusoe, E.3
  • 61
    • 77953229623 scopus 로고    scopus 로고
    • Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts
    • Lee YC, Huang CF, Murshed M, et al,. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 2010; 29: 3196-3207.
    • (2010) Oncogene , vol.29 , pp. 3196-3207
    • Lee, Y.C.1    Huang, C.F.2    Murshed, M.3
  • 62
    • 33751028441 scopus 로고    scopus 로고
    • Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
    • Wilson GR, Cramer A, Welman A, et al,. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 2006; 95: 1410-1414.
    • (2006) Br J Cancer , vol.95 , pp. 1410-1414
    • Wilson, G.R.1    Cramer, A.2    Welman, A.3
  • 63
    • 31544460437 scopus 로고    scopus 로고
    • Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression
    • Diaz N, Minton S, Cox C, et al,. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006; 12: 20-28.
    • (2006) Clin Cancer Res , vol.12 , pp. 20-28
    • Diaz, N.1    Minton, S.2    Cox, C.3
  • 64
    • 0036890288 scopus 로고    scopus 로고
    • Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma
    • Ito Y, Kawakatsu H, Takeda T, et al,. Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma. Breast Cancer Res Treat 2002; 76: 261-267.
    • (2002) Breast Cancer Res Treat , vol.76 , pp. 261-267
    • Ito, Y.1    Kawakatsu, H.2    Takeda, T.3
  • 65
    • 29044442658 scopus 로고    scopus 로고
    • Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma
    • Madan R, Smolkin MB, Cocker R, et al,. Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma. Hum Pathol 2006; 37: 9-15.
    • (2006) Hum Pathol , vol.37 , pp. 9-15
    • Madan, R.1    Smolkin, M.B.2    Cocker, R.3
  • 66
    • 84857923923 scopus 로고    scopus 로고
    • Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence
    • Han K, Nofech-Mozes S, Narod S, et al,. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol) 2012; 24: 183-189.
    • (2012) Clin Oncol (R Coll Radiol) , vol.24 , pp. 183-189
    • Han, K.1    Nofech-Mozes, S.2    Narod, S.3
  • 67
    • 0033549344 scopus 로고    scopus 로고
    • Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
    • Fisher B, Dignam J, Wolmark N, et al,. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.
    • (1999) Lancet , vol.353 , pp. 1993-2000
    • Fisher, B.1    Dignam, J.2    Wolmark, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.